Ushering out the old and ringing in the new! The New Year holds promise to be an exciting year, filled with innovation and opportunities within the aHUS community in America and beyond! Not that 2015 was dreary, as a matter of fact it proved quite the opposite.
In 2015 there were 20 aHUS regional meetings schedules across the USA, hosted by NORD and Global…
Added by Linda Burke on December 28, 2015 at 12:00am — No Comments
As 2015 draws to a close, it seems likely that 2016 will bring progress in complement therapeutics development toward clinical use. Since a hallmark of aHUS is chronic, uncontrolled complement activation, we’re looking forward to what happens in a rapidly moving field which seems promise advancement soon. (FMI Click Here) As with eculizumab (Soliris ®, from Alexion Pharmaceuticals), we likely will see clinical trials…Continue
Added by Linda Burke on December 27, 2015 at 9:00pm — No Comments
As we approach this holiday season, Jana Dodd, reminds us to "Count Your Many Blessings".
In our aHUS community, we often appreciate more of the small things, the mini milestones, and the everyday accomplishments. This is such a gift that we have be given. Everyday is a blessing.
With that said, our first aHUStonishing hero is the sweet Eliza.…Continue
Added by Donna Kolp on December 20, 2015 at 2:54pm — No Comments
Hey everybody, It's been a long time since I've provided an update on how things are for me so I wanted to take some time to do that. This last quarter of the year, has undoubtedly been the hardest for me since being diagnosed. I've held on to faith and hope that treatment would keep me going but my circumstances have been less than ideal.
I just ended my (hopefully) last fall semester of college, and it definitely gave me a run for my money. In October I was asked to be a…Continue
Added by Megan Russo on December 17, 2015 at 5:50pm — No Comments
Earlier this December I was honored to attend the ASH (American Society of Hematology) conference. I was blown away by the amount of people who attended and humbled to speak with doctors to gain information on the newest technologies for aHUS. The first day there we had a lot of doctors from other countries approach our booth who did not have access to treatment. The remainder of the event we had many doctors and researchers approach us that did not know the foundation existed. Overall, ASH…Continue
Added by Megan Russo on December 17, 2015 at 4:03pm — No Comments
Just recently I was asked to tell my story and speak on behalf of the atypical HUS Foundation at the Phoenix meet up.
My husband and I are from the Dallas Texas area, so we flew out to Phoenix first thing Friday, December 4. We got checked into our hotel and attended the dinner provided by Global Genes. During the dinner, we had an "ice breaking" type activity. The goal was to introduce yourself to the group, tell where you are from, and tell an embarrassing story about…Continue
Added by Amber S Schlaht on December 16, 2015 at 11:56am — No Comments
Achillion Pharmaceuticals, Inc. distributed a press release on the first day of the American Society of Hematology meeting which was held December 5-8, 2015 in Orlando Florida. In their December 5th 2015 press release, they announced that their company would present information regarding Achillion’s small-molecule factor D inhbitors at the 57th Annual Meeting of the ASH.…Continue
In a Dec 5, 2015 press release, Akari Therapeutics announced that they will present new data about the efficiacy of Coversin in eculizumab resistant patients at the 57th American Society of Hematology (ASH) Annual Meeting taking place in Orlando from December 5-8.
Coversin inhibits complement C5 activity, and is described…Continue
Alnylam Pharmaceuticals has announced that Alnylam scientists and collaborators will present at ASH the new results from ongoing clinical studies, to include a poster session of particular interest to the aHUS community. One of its two of its subcutaneously administered investigational drugs, ALN-CC5, currently being explored within the context of paroxysmal…Continue
Added by Linda Burke on December 4, 2015 at 3:30pm — No Comments
Ra Pharmaceuticals announced today the launch of a Phase 1 study of its C5 complement inhibitor RA101495. From the…Continue